Rodman & Renshaw Starts CorMedix (CRMD) at Buy
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $8.14 +14.65%
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Rodman & Renshaw analyst Brandon Folkes initiates coverage on CorMedix (NASDAQ: CRMD) with a Buy rating and a price target of $13.00.
For an analyst ratings summary and ratings history on CorMedix click here. For more ratings news on CorMedix click here.
Shares of CorMedix closed at $5.65 yesterday.
You May Also Be Interested In
- CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
- Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight
- Canaccord Starts Kazia Therapeutics (KZIA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
